Sample preparation remains essential for high-quality mass spectrometry proteomics. Here, we compared three commonly used methods for protein extraction of frozen mammalian tissues: 1) extraction using SDS buffer followed by…
Read More
While computational genomics methods have been greatly advanced by open development in distributed computing environments, computational tools for mass spectrometry proteomics remain tethered to proprietary and often outdated operating systems.…
Read MoreA few years ago, we published a paper reporting PGBD5 as an oncogenic mutator in human cancer. This included measuring its expression in human tissues and mapping its association with…
Read MoreGenetically engineered mouse models of human cancers have proven to be essential for the elucidation of basic molecular mechanisms of cancer pathogenesis and their therapeutic targeting. However, for many genetic…
Read MoreRecent developments in quantitative high-resolution mass spectrometry have led to significant improvements in the sensitivity and specificity of biochemical analyses of cellular reactions, protein-protein interactions, and small molecule drug discovery.…
Read MoreIn high-risk cirrhotic patients, we have the opportunity to dramatically reduce the burden of cancer via prevention. We asked if immunotherapy could be safe and effective for HCC prevention. In our murine models of HCC, it is! Congrats Andrew Chung + team!
https://cancerpreventionresearch.aacrjournals.org/content/early/2020/10/13/1940-6207.CAPR-20-0200
I’m thrilled to announce that we are recruiting a new faculty member to the Pathology department @DanaFarber @harvardmed !! Job ID 20762
Please retweet the news! #facultyjobs #higheredjobs #cancerresearch https://careers.dana-farber.org/job/assistant-associate-professor-department-of-oncologic-pathology-faculty-health-educator-450-brookline-ave-b-5-20762/
A beautiful AML clonal evolution story by @lindemilesphd And @bowman_rl (@rosslevinemd @RossLevineLab ) out today. Congratulations to the team!
https://www.nature.com/articles/s41586-020-2864-x
BEAT-AML trial provides proof of principle for a precision medicine for pts aged >60 yrs with AML: 95% has molecular profiling completed within 7 days and 30-day mortality was lower in the 57% of pts who received targeted therapy (3.7% vs 20.4% with SOC) - https://www.nature.com/articles/s41591-020-1089-8?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NRRJ_2_SJB_nrclinonc_editorial_socialposts
Must read https://www.statnews.com/2020/10/27/akiko-iwasaki-profile-covid19-research-fighting-sexism-power-imbalances-science/
